DoW Ovarian Cancer, Clinical Trial Award

The Fiscal Year 2026 Congressionally Directed Medical Research Programs' Ovarian Cancer Research Program (OCRP) outlines five distinct award mechanisms: Clinical Trial Award, Investigator-Initiated Research Award, Ovarian Cancer Academy – Early-Career Investigator Award, Ovarian Cancer Clinical Trial Academy – Early Career Investigator Award, and Pilot Award. Each mechanism details specific eligibility criteria, key program elements, funding limits, and submission deadlines. The Clinical Trial Award supports rapid implementation of clinical trials with up to $2.8 million over 4 years. The Investigator-Initiated Research Award, with funding up to $1.05M for single PIs and $1.40M for partnering PIs over 4 years, focuses on high-impact research excluding clinical trials. Early-career investigators can apply to the Ovarian Cancer Academy Awards, offering intensive mentoring and funding up to $1.125M for non-clinical and $1.4M for clinical trials, both for 4 years. The Pilot Award supports innovative, high-risk/high-reward research up to $350,000 over 2 years, with no preliminary data required and blinded review. All awards specify total costs include direct and indirect costs, and pre-application submissions are required for most mechanisms.

The Fiscal Year 2026 Congressionally Directed Medical Research Programs Ovarian Cancer Research Program (OCRP) outlines five distinct award mechanisms for ovarian cancer research: Clinical Trial Award, Investigator-Initiated Research Award, Ovarian Cancer Academy – Early-Career Investigator Award, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award, and Pilot Award. Each mechanism has specific eligibility criteria, key elements, funding limits (ranging from $350,000 to $2.8 million over 2 to 4 years), and submission deadlines in 2026. The awards support various research types, including clinical trials, high-impact investigator-initiated research, and early-career investigator development through virtual academies with mentoring. Preliminary data is often required, and some mechanisms prohibit clinical trials or require pre-proposals/letters of intent. The program emphasizes innovation, support for early-career investigators, and research to extend the lives of advanced-state and recurrent ovarian cancer patients.